Drug
AZD6234 clinical trials
Also written AZD6234.
- studies test it
- 12
- open now
- 3
- in phase 3
- 2
- first study started
- 2022
Keep track of what changes. Save the AZD6234 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AZD6234
- 12
Studies by the year they started
12 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AZD6234 is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234RecruitingPhase 1AstraZenecaNCT07546760Written as AZD6234
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightRecruitingPhase 3AstraZenecaNCT07784270Written as AZD6234
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07784725Written as AZD6234
- A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234CompletedPhase 1AstraZenecaNCT07220954Written as AZD6234 Formulation 1
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityActive, not recruitingPhase 1AstraZenecaNCT07013643Written as AZD6234
- A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityCompletedPhase 2AstraZenecaNCT06595238Written as AZD6234
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightActive, not recruitingPhase 2AstraZenecaNCT07017179Written as AZD6234
- Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistCompletedPhase 2AstraZenecaNCT06851858Written as AZD6234
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneCompletedPhase 2AstraZenecaNCT06862791Written as AZD6234
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseCompletedPhase 1AstraZenecaNCT06132841Written as AZD6234
- Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234CompletedPhase 1AstraZenecaNCT06845813Written as AZD6234
- Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseCompletedPhase 1AstraZenecaNCT05511025Written as AZD6234